Teva Pharmaceutical Industries Limited (NYSE:TEVA) is at least 1.07% than its current record low price of $7.46. There was a -0.79% decline on 7/26/2019 that led the price to move at $7.54. At a recent session, the prices were hovering between $7.48 and $7.68. This company shares are 79.97% off its target price of $13.57 and the current market capitalization stands at $8.63B. The recent change has given its price a -17.95% deficit over SMA 50 and -70.96% deficit over its 52-week high. The stock witnessed -15.19% declines, -50.91% declines and -61.45% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found TEVA’s volatility during a week at 4.52% and during a month it has been found around 4.44%.

What Does Teva Pharmaceutical Industries Limited (TEVA) Do?

The company describes itself in regulatory filings as, “Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which engages in development, production and marketing of drugs, generic drugs, over-the-counter drugs, active ingredients for the pharmaceutical industry (APIs) and therapeutic products. It operates through two segments: Generic Medicines and Specialty Medicines. The Generic Medicines segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty Medicine segment engages in the provision of core therapeutic areas of central nervous system medicines. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.” [Text can be found here: https://www.marketwatch.com/investing/stock/TEVA/profile under company description.]

Teva Pharmaceutical Industries Limited (TEVA) Top Holders

Institutional investors currently hold around $5.11 billion or 62.8% in TEVA stock. Look at its top three institutional owners: Capital Research Global Investors owns $966.56 million in Teva Pharmaceutical Industries Limited, which represents roughly 11.2% of the company’s market cap and approximately 18.9% of the institutional ownership. Similar statistics are true for the second largest owner, Franklin Resources Inc, which owns 64,623,884 shares of the stock are valued at $487.26 million. The third largest holder is Wellington Management Group Llp, which currently holds $441.06 million worth of this stock and that ownership represents nearly 5.11% of its market capitalization.

Teva Pharmaceutical Industries Limited 13F Filings

At the end of March reporting period, 223 institutional holders increased their position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by some 69,700,642 shares, 247 decreased positions by 94,914,639 and 114 held positions by 513,476,247. That puts total institutional holdings at 678,091,528 shares, according to SEC filings. The stock grabbed 49 new institutional investments totaling 16,754,363 shares while 82 institutional investors sold out their entire positions totaling 16,492,179 shares.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Insider Trades

Multiple company employees have indulged in significant insider trading. Teva Pharmaceutical Industries Limited disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director BARER SOL J has acquired 104,500 shares of Teva Pharmaceutical Industries Limited (TEVA) in the trading session dated Jun. 04, 2019. These shares are worth $1,003,200 and were traded at $9.6 each. The SEC filing shows that BARER SOL J performed a purchase of 111,000 shares. The Director added these shares by way of transaction on Jun. 03, 2019. The company’s shares were assimilated at $8.98 per share worth to an investment of some $996,780 to the account of BARER SOL J.

Executive VP Global Operations, de Notaristefani Carlo, sold 16,070 common shares of Teva Pharmaceutical Industries Limited (TEVA) in the open market. In a transaction dated May. 20, 2019, the shares were put up for sale at an average price of $11.42, raking in a sum of $183,519. After this sale, 33,589 common shares of TEVA are directly owned by the insider, with total stake valued at $253,259.

In the transaction dated May. 16, 2019, a great number of shares sold came courtesy the Executive VP Global Operations; de Notaristefani Carlo disposed a total of 629 shares at an average price of $11.76, amounting to approximately $7,397. The insider now directly owns 18,784 shares worth $141,629.

Teva Pharmaceutical Industries Limited (TEVA) Analyst Guide

Several analysts have released their opinion on Teva Pharmaceutical Industries Limited (NYSE:TEVA), with 3 analysts believing it is a strong buy. Whereas 16 of them predict the stock is a hold. Also, there are 3 buy, 5 sell and 0 strong sell ratings, collectively assigning a 2.85 average brokerage recommendation [T1].